Invuity, Inc. (IVTY) Reaches $3.75 1 Year Low; 8 Bullish Analysts Covering RedHill Biopharma Ltd. (RDHL)

February 15, 2018 - By Vivian Currie

Among 8 analysts covering RedHill Biopharma (NASDAQ:RDHL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 14 analyst reports since July 29, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $3300 target in Thursday, June 15 report. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) has “Outperform” rating given on Friday, February 24 by FBR Capital. The company was initiated on Tuesday, September 29 by Northland Capital. On Thursday, June 15 the stock rating was maintained by FBR Capital with “Buy”. The stock has “Buy” rating by Roth Capital on Tuesday, November 14. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) earned “Buy” rating by TH Capital on Wednesday, July 29. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) has “Sell” rating given on Saturday, August 22 by Zacks. The stock has “Hold” rating by TheStreet on Tuesday, August 25. Roth Capital maintained RedHill Biopharma Ltd. (NASDAQ:RDHL) rating on Monday, July 31. Roth Capital has “Buy” rating and $2700 target. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) earned “Buy” rating by Nomura on Tuesday, September 29. See RedHill Biopharma Ltd. (NASDAQ:RDHL) latest ratings:

26/01/2018 Broker: Nomura Rating: Buy New Target: $18 Initiates Coverage On
14/11/2017 Broker: Roth Capital Rating: Buy New Target: $20.0 Maintain
06/10/2017 Broker: Seaport Global Rating: Buy New Target: $19 Initiates Coverage On

The stock of Invuity, Inc. (NASDAQ:IVTY) hit a new 52-week low and has $3.49 target or 7.00% below today’s $3.75 share price. The 5 months bearish chart indicates high risk for the $64.27M company. The 1-year low was reported on Feb, 15 by Barchart.com. If the $3.49 price target is reached, the company will be worth $4.50 million less. The stock decreased 2.60% or $0.1 during the last trading session, reaching $3.75. About 68,710 shares traded. Invuity, Inc. (NASDAQ:IVTY) has risen 50.92% since February 15, 2017 and is uptrending. It has outperformed by 34.22% the S&P500.

The stock decreased 0.08% or $0.0048 during the last trading session, reaching $5.8952. About 6,230 shares traded. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 9.09% since February 15, 2017 and is downtrending. It has underperformed by 25.79% the S&P500.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $122.58 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: